CNS Plasticity of Human Adipo-derived Multipotent Cells
人脂肪来源的多能细胞的中枢神经系统可塑性
基本信息
- 批准号:6670832
- 负责人:
- 金额:$ 18.05万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-08-01 至 2005-07-31
- 项目状态:已结题
- 来源:
- 关键词:adipose tissue axon brain cell brain injury cell differentiation cell migration cell proliferation cell sorting cell transplantation cell type central nervous system clinical research confocal scanning microscopy electrophysiology fluorescence microscopy human tissue immunocytochemistry laboratory rat neural plasticity neurogenesis neurons phenotype
项目摘要
DESCRIPTION (provided by applicant):
Stem cells and regenerative cell therapies hold great promise for treating a variety of disorders; however, an optimal cell source for translating this promise into the clinical realm remains to be determined. The use of embryonic stem cells is fraught with ethical and political controversy, and these cells present several practical issues, including adequacy of supply and non-autologous tissue responses. Adult stem cells offer a less controversial, and potentially autologous, solution; but their utility may be restricted by a limited range of developmental plasticity and an inadequacy of supply. An ideal source of cells would be abundant, expendable, replenishable, autologous, and should be easy and safe to harvest. The cells should possess considerable growth capacity, developmental plasticity, and ideally would be free of ethical and political constraints. Recently, we have demonstrated the existence of multipotent cells within human subcutaneous adipose tissue. These cells have the capacity for extensive growth, renewal, and can differentiate in vitro along ectodermally and mesodermally derived lineages. Moreover, adipose tissue represents an abundant, autologous source of cells, which can be easily and safely harvested. The studies proposed in this R21 application will investigate the plasticity of adult human adipo-derived cells (hADCs) in the rat central nervous system, hADCs are capable of differentiating into cells with neural phenotypes in vitro. Preliminary findings indicate that hADCs survive injection into the brain, migrate long distances in naive and injured (post-ischemic) brains, exhibit targeted migration to regions of injury, and survive for at least 10 weeks in vivo (the longest period tested to date). The central hypothesis of this application is that hADCs can engraft and migrate in the central nervous system, exhibit targeted migration to areas of cerebral injury, differentiate into neural cell types, and exhibit long-term survival. This hypothesis will be evaluated in the context of two specific aims. Aim 1 will identify the phenotypic and positional fates of hADCs implanted into the CNS of naive (i.e. uninjured) rats. Aim 2 will identify the phenotypic and positional fates of hADCs implanted into rat CNS after injurious transient ischemia. The results of these studies will provide the first evidence of hADC plasticity in the brain and could form the foundation for future cell-based therapies in the CNS.
描述(由申请人提供):
干细胞和再生细胞疗法在治疗各种疾病方面大有可为;然而,将这一前景转化为临床领域的最佳细胞来源仍有待确定。胚胎干细胞的使用充满了伦理和政治争议,这些细胞存在几个实际问题,包括供应充足和非自体组织反应。成体干细胞提供了一种争议性较小且可能是自体的解决方案;但它们的用途可能受到发育可塑性范围有限和供应不足的限制。理想的细胞来源应该是丰富的、可消耗性的、可补充的、自体的,并且应该容易和安全地采集。细胞应该具有相当大的生长能力、发育可塑性,理想情况下不受伦理和政治限制。最近,我们证实了人类皮下脂肪组织中存在多能细胞。这些细胞具有广泛的生长、更新能力,并能沿着外胚层和中胚层来源的谱系在体外分化。此外,脂肪组织是一种丰富的自体细胞来源,可以轻松安全地获取。这项R21应用中提出的研究将探讨成年人类脂肪来源细胞(HADC)在大鼠中枢神经系统中的可塑性,hADC在体外能够分化为具有神经表型的细胞。初步研究结果表明,hADC注射入脑后存活,在幼稚和受损(缺血后)脑中长距离迁移,有针对性地迁移到损伤区域,并在体内存活至少10周(迄今为止测试的最长时间)。这一应用的中心假设是hADC可以在中枢神经系统中移植和迁移,表现出向脑损伤区域的靶向迁移,分化为神经细胞类型,并表现出长期存活。这一假设将在两个具体目标的背景下进行评估。目的1鉴定hADC植入幼年(即未损伤)大鼠中枢神经系统的表型和定位命运。目的2鉴定hADC在损伤性短暂性脑缺血后植入大鼠中枢神经系统的表型和定位命运。这些研究的结果将为hADC在大脑中的可塑性提供第一个证据,并可能为未来中枢神经系统的基于细胞的治疗奠定基础。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
KEVIN Scott LEE其他文献
KEVIN Scott LEE的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('KEVIN Scott LEE', 18)}}的其他基金
Precise, non-invasive, axon-sparing surgery for the treatment of drug resistant epilepsy
精确、非侵入性、保留轴突的手术治疗耐药性癫痫
- 批准号:
9894855 - 财政年份:2018
- 资助金额:
$ 18.05万 - 项目类别:
Precise, non-invasive, axon-sparing surgery for the treatment of drug resistant epilepsy
精确、非侵入性、保留轴突的手术治疗耐药性癫痫
- 批准号:
10357887 - 财政年份:2018
- 资助金额:
$ 18.05万 - 项目类别:
Precise, non-invasive, axon-sparing surgery for the treatment of drug resistant epilepsy
精确、非侵入性、保留轴突的手术治疗耐药性癫痫
- 批准号:
10115826 - 财政年份:2018
- 资助金额:
$ 18.05万 - 项目类别:
Utility of a Novel Carotenoid for Treating Stroke
新型类胡萝卜素治疗中风的效用
- 批准号:
7872312 - 财政年份:2008
- 资助金额:
$ 18.05万 - 项目类别:
Utility of a Novel Carotenoid for Treating Stroke
新型类胡萝卜素治疗中风的效用
- 批准号:
7463158 - 财政年份:2008
- 资助金额:
$ 18.05万 - 项目类别:
Utility of a Novel Carotenoid for Treating Stroke
新型类胡萝卜素治疗中风的效用
- 批准号:
7795733 - 财政年份:2008
- 资助金额:
$ 18.05万 - 项目类别:
Utility of a Novel Carotenoid for Treating Stroke
新型类胡萝卜素治疗中风的效用
- 批准号:
7591138 - 财政年份:2008
- 资助金额:
$ 18.05万 - 项目类别:
Neurological Impact of Cardiopulmonary Bypass Surgery
心肺搭桥手术对神经系统的影响
- 批准号:
7140779 - 财政年份:2006
- 资助金额:
$ 18.05万 - 项目类别:
Neurological Impact of Cardiopulmonary Bypass Surgery
心肺搭桥手术对神经系统的影响
- 批准号:
7243333 - 财政年份:2006
- 资助金额:
$ 18.05万 - 项目类别:
Neurological Impact of Cardiopulmonary Bypass Surgery
心肺搭桥手术对神经系统的影响
- 批准号:
7446775 - 财政年份:2006
- 资助金额:
$ 18.05万 - 项目类别:
相似海外基金
An atypical microtubule generation mechanism for neurons drives dendrite and axon development and regeneration
神经元的非典型微管生成机制驱动树突和轴突的发育和再生
- 批准号:
23K21316 - 财政年份:2024
- 资助金额:
$ 18.05万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Characterizing Wnt Signaling Pathways in Axon Guidance
轴突引导中 Wnt 信号通路的特征
- 批准号:
10815443 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
2023 NINDS Landis Mentorship Award - Administrative Supplement to NS121106 Control of Axon Initial Segment in Epilepsy
2023 年 NINDS 兰迪斯指导奖 - NS121106 癫痫轴突初始段控制的行政补充
- 批准号:
10896844 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
Does phosphorylation regulation of the axon initial segment cytoskeleton improve behavioral abnormalities in ADHD-like animal models?
轴突起始段细胞骨架的磷酸化调节是否可以改善 ADHD 样动物模型的行为异常?
- 批准号:
23KJ1485 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
Grant-in-Aid for JSPS Fellows
Loss-of-function variants of the axon death protein SARM1 and protection from human neurodegenerative disease
轴突死亡蛋白 SARM1 的功能丧失变体和对人类神经退行性疾病的保护
- 批准号:
2891744 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
Studentship
Collaborative Research: Evolution of ligand-dependent Robo receptor activation mechanisms for axon guidance
合作研究:用于轴突引导的配体依赖性 Robo 受体激活机制的进化
- 批准号:
2247939 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
Standard Grant
Understanding the degeneration of axon and nerve terminals in Alzheimer's disease and related dementia brain
了解阿尔茨海默病和相关痴呆大脑中轴突和神经末梢的变性
- 批准号:
10661457 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
Unlocking BIN1 function in oligodendrocytes and support of axon integrity
解锁少突胶质细胞中的 BIN1 功能并支持轴突完整性
- 批准号:
10901005 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
Regulating axon guidance through local translation at adhesions
通过粘连处的局部翻译调节轴突引导
- 批准号:
10587090 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
The role of RNA methylation in cytoskeleton regulation during axon development
RNA甲基化在轴突发育过程中细胞骨架调节中的作用
- 批准号:
22KF0399 - 财政年份:2023
- 资助金额:
$ 18.05万 - 项目类别:
Grant-in-Aid for JSPS Fellows














{{item.name}}会员




